Protect yourself by obtaining a vaccination against COVID-19 and the Delta strain if you are 12 years or older; seek urgent care if needed The world, the country and our area continue to experience an increase in COVID-19 cases and hospitalizations with the highly contagious Delta SARS-CoV-2 virus strain. The Renown Health team continues to safely screen, diagnose and care for patients with respiratory illnesses, including those at risk for COVID-19. Renown continues to use current local and national data, analytics, and public data sets for predictive modeling in service to our community. Renown Health ensures constant readiness by working closely with the Washoe County Health District, the Governor’s office, and is informed by updates from the Centers for Disease Control and Prevention (CDC). When there is heightened concern around an illness, we implement enhanced infection prevention strategies to ensure we are ready with the appropriate supplies and alternate plans should the need arise. Renown Health providers are educated and prepared to quickly and safely screen, diagnose and care for patients with respiratory illness, including COVID-19. Vaccination is the best protection against Delta. “The most important action you can take to protect yourself from the Delta strain and the COVID-19 virus is to get fully vaccinated,” says Brion Hill, MD who practices at the Renown Urgent Care - Los Altos location. “The COVID 19 virus and Delta strain is preventable and controllable through safe and effective COVID-19 vaccines, which are free and now widely available in our area. The CDC recommends all people 12 years and older be vaccinated against COVID-19. Recent data show that nearly all COVID-19 deaths are now occurring among unvaccinated individuals.” A list of providers in our area offering vaccines is available at vaccines.gov.” Protecting Yourself, Friends and Family Dr. Hill adds, “You can protect yourself the same way you would protect against other viruses with a few common-sense practices.” Wear a cloth mask or medical procedure mask when in a public setting. For situations when you are in close contact with people who do not live with you, you may want to consider a mask option that provides a higher level of protection (improved fit and/or improved filtration). Wash your hands thoroughly and often. Make sure you are cleaning between your fingers and under your nails. Use alcohol-based sanitizers when soap and water are not available. Use disposable tissues when coughing and sneezing; dispose of carefully and promptly. If tissues are not available, direct your cough or sneeze into the crook of your arm/sleeve. Avoid touching your eyes, nose, and mouth with unwashed hands. Clean and disinfect frequently touched objects and surfaces. Avoid close contact with anyone who has cold or flu-like symptoms. Avoid shaking hands, especially with those who appear to be ill. Disinfect shared surfaces. Practice social distancing, 6 feet or more. Stay home when you are sick. If you have fever, cough, gastrointestinal, or respiratory symptoms please call your medical provider and explain your symptoms before coming in to their offices. If you do not have a health care provider, and have medical concerns that are urgent but not life-threatening, visit a Renown Urgent Care physician or healthcare provider. Virtual Urgent Care is available for people for COVID-19 symptoms and Virtual Urgent Care visits are available through MyChart. MyChart is a free, secure online patient portal that allows you to access your Renown Health medical record and manage your health care information. There are 11 conveniently located Renown Urgent Care offices with providers ready to see you 7 days a week. You have the option to book ahead and schedule an appointment at 11 locations near you. How to Get Accurate and Reliable Information: We continue to advise our community regarding the importance of accurate sources of information, and to provide regular updates. For up-to-date information on Renown’s approach to keeping our community safe, visit our website at renown.org. About Renown Health Renown Health is a locally governed, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, the region’s only children’s hospital, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to improving the care and the health of our community. For more information, visit renown.org.
Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.” About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org and follow Dr. Tony Slonim on Twitter @RenownCEOTonyMD. About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.Additional Media Contact:Sung Lee, Investors 650-524-7792Arran Attridge, Media 650-425-8975